While long-term follow up of ADA-SCID patients showed the safety of the therapy, three cases (out of 67 treated patients) of myelodysplastic syndrome (MDS) due to insertional mutagenesis were recently reported in ALD (40, 41). The gene discussed is ADA; the disease is adrenoleukodystrophy.